Nova Mentis Life Science Corp.

Recent News

  • Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application

    Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined manufacturing processes and product specifications as outlined in chemistry, manufacturing and controls (CMC) published guidelines."NOVA has accomplished a major...

    2022-09-29 8:30 AM EDT
  • Nova Mentis Completes Production of Psilocybin Microdose Capsules

    Vancouver, British Columbia--(Newsfile Corp. - September 15, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology (TIPT®).TIPT and NOVA have recently completed the manufacturing of an engineering quantity of the psilocybin microdose capsules that...

    2022-09-15 8:30 AM EDT
  • Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a poster presentation at the 18th NFXF International Fragile X...

    2022-07-11 8:30 AM EDT
  • Nova Mentis to Present at the H.C. Wainwright Mental Health Conference

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it will be presenting at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022. The NOVA presentation is titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome.NOVA...

    2022-06-22 8:30 AM EDT
  • Nova Mentis dépose un brevet portant sur le diagnostic, la surveillance et le traitement des maladies neurologiques à l'aide de dérivés psychoactifs de la tryptamine

    Vancouver, British Columbia--(Newsfile Corp. - 16 juin 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB : NMLSF) (« NOVA » ou la « Société »), une société de biotechnologie et leader mondial des thérapies à base de psilocybine et des diagnostics complémentaires de premier ordre pour les troubles neuro-inflammatoires, est heureuse d'annoncer qu'elle renforce sa propriété intellectuelle grâce au dépôt de demandes de brevets provisoires afin de protéger les données qu'elle a obtenues au cours de ses études précliniques sur...

    2022-06-16 8:30 AM EDT
  • Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

    Vancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its IP with the filing of provisional patent applications to protect data it obtained during its psilocybin preclinical studies and provide protection for the Company's therapeutic paradigm for treating neuroinflammatory disorders with psilocybin...

    2022-06-16 8:30 AM EDT
  • Nova Mentis et la University of Central Florida vont développer un test permettant de mesurer la sérotonine dans la salive

    Vancouver, British Columbia--(Newsfile Corp. - 9 juin 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB : NMLSF) (« NOVA » ou la « Société »), une société de biotechnologie et leader mondial des thérapies à base de psilocybine et des diagnostics complémentaires de premier ordre pour les troubles neuro-inflammatoires, est heureuse d'annoncer qu'elle a signé un accord de recherche avec la University of Central Florida (UCF) Research Foundation afin d'étudier le dosage de la sérotonine dans la salive.Le Dr Kiminobu...

    2022-06-09 8:30 AM EDT
  • Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

    Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay.Dr. Kiminobu Sugaya, a Professor and Head of Neuroscience in the Burnett School of Biomedical...

    2022-06-09 8:30 AM EDT